Antipsychotic Withdrawal Symptoms: A Systematic Review and Meta-Analysis

However, there is still a possibility of severe reactions and withdrawal symptoms. Patient and clinician education are needed so that patients taking benzodiazepinesare aware of both their appropriate and time-limited use and the risks involved ifexposure is prolonged. Further research into protracted benzodiazepine withdrawal isurgently needed. A slow tapermay help reduce the duration, number, and intensity of symptoms but does notnecessarily prevent them. Since even a gradual taper can be a difficult lifeexperience for the patient, collaboration between patient and prescriber is needed,including unbiased listening to and hearing their stories, plus individualizedcare.

Data Sources

The risk of acute dystonia can be largely mitigated by using SGAs 30. Psychotic decompensation appeared to develop simultaneously with extrapyramidal symptoms (EPS) in some patients, but only 14.2 per cent of the placebo group experienced extrapyramidal symptoms severe enough to require resumption of benztropine therapy. In addition, there is no evidence to support the suggestion that the withdrawal of these medications may benefit people with TD. People with TD could consider these as other experimental treatments for which very little supportive data exist. Where assumptions had to be made regarding people lost to follow‐up (see Dealing with missing data) we compared the findings when we https://ecosoberhouse.com/ used our assumption with ‘completer’ data only.

Authors’ contributions

Also, carry‐over may involve the re‐growth or retreat of neuroreceptors. This slow re‐balancing, if started, could continue long after all traces of intervention drugs are gone, so physiological half life of the experimental treatment may not be the only variable to consider when thinking though the issues of carry‐over. TD is also an unstable condition and people with TD may not remain compliant with medication. All these factors make the arguments for not using cross‐over methodology strong, despite the initial attraction (Armitage 1991; Fleiss 1984; Pocock 1983).

Characteristics of included studies ordered by study ID

We have defined clinical efficacy as an improvement in the symptoms of TD of more than 50%, on any scale. We grouped outcomes into short term (less than 6 weeks), medium term (between 6 weeks and six months) and long term (more than six months). Anticholinergic drugs (benzhexol, benztropine, biperiden, dexetimide, orphenadrine, procyclidine, scopolamine, trihexyphenidyl) compared to placebo, or no intervention;
ii.

The intrinsic anticholinergic properties of the antipsychotics themselves and concomitant medications, such as antidepressants, appeared protective against development of EPS. Most patients on a combination of antipsychotics and anticholinergics can safely be withdrawn from the latter. If parkinsonism reemerges, amantadine can be considered to help manage the movements while gradual tapering of the remaining anticholinergic medication continues. In the event that antipsychotics are also discontinued, anticholinergics should be continued for an additional 48–72 hours to prevent emergence or recurrence of acute dystonia. Due to the extended half-lives of most DRBAs, break-through dystonic reactions can occur if both drugs are discontinued simultaneously 105, 106. There is insufficient evidence for changing antipsychotic regimens or discontinuing antipsychotics to treat TD 63–65.

• Enhance Reviews Ltd. is a private company that performs systematic reviews of literature.
• And Brooks (24); Table 1) were cohort studies setting the participants to placebo (i.e., target group) and no control group that continued the antipsychotic.
• Eighteen of twenty patients successfully discontinued their anticholinergic.
• Such a phenomenon is also seen in some individuals with alcohol problems in which such kindling is better understood.
• 8.2 Average score/change in social confidence, social inclusion, social networks, or personalised quality of life measures.

The reviewers independently evaluated the quality of all included trials. A rating was given for each trial based on the three benztropine withdrawal quality categories as described in the Cochrane Collaboration Handbook (Mulrow 1999). Only trials stated to be randomized (category A or B of the Handbook) were included in this review. We wish to thank Rosie Asher for screening literature and helping with data extraction.

Ludatscher 1989 published data only

Based on the results of the above studies, in a recent review we suggested a trial of gradual anticholinergic discontinuation in patients with stable movement disorders Desmarais et al. 2012. Most studies of anticholinergic withdrawal in schizophrenia have not used very descriptive scales for the measurement of EPS and few have conjointly evaluated cognition. This study, a prospective open study of anticholinergic agent discontinuation, does both.

Avoiding withdrawal symptoms following antipsychotic discontinuation is an important factor when planning a safe therapy. We performed a systematic review and meta-analysis concerning occurrence what is alcoholism of withdrawal symptoms after discontinuation of antipsychotics. The strongest evidence for prophylactic anticholinergic use is for the prevention of acute dystonia in at-risk individuals (e.g., young, male) 30, 47.

We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise and discussed in the text if they arose. We reported and used data where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported. At some degree of loss to follow‐up, data must lose credibility (Xia 2009).